FR3048286B1 - Peptides immunogenes et leur utilisation - Google Patents

Peptides immunogenes et leur utilisation Download PDF

Info

Publication number
FR3048286B1
FR3048286B1 FR1651610A FR1651610A FR3048286B1 FR 3048286 B1 FR3048286 B1 FR 3048286B1 FR 1651610 A FR1651610 A FR 1651610A FR 1651610 A FR1651610 A FR 1651610A FR 3048286 B1 FR3048286 B1 FR 3048286B1
Authority
FR
France
Prior art keywords
peptides
value
formation
ratio
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1651610A
Other languages
English (en)
Other versions
FR3048286A1 (fr
Inventor
Pierre-Alain Rubbo
Edouard Tuaillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omunis
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
AxLR SATT du Languedoc Roussillon SAS
Original Assignee
Omunis
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
AxLR SATT du Languedoc Roussillon SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1651610A priority Critical patent/FR3048286B1/fr
Application filed by Omunis, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, AxLR SATT du Languedoc Roussillon SAS filed Critical Omunis
Priority to PCT/FR2017/050418 priority patent/WO2017144830A1/fr
Priority to CA3014034A priority patent/CA3014034A1/fr
Priority to EP17712193.6A priority patent/EP3420358A1/fr
Priority to CN201780013116.0A priority patent/CN108885213A/zh
Priority to US16/079,629 priority patent/US20210199657A1/en
Priority to JP2018544825A priority patent/JP2019511708A/ja
Publication of FR3048286A1 publication Critical patent/FR3048286A1/fr
Application granted granted Critical
Publication of FR3048286B1 publication Critical patent/FR3048286B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode de criblage in vitro de peptides immunogènes d'intérêt capables de reconnaitre des anticorps issus du sérum d'individus atteints de tuberculose active, ladite méthode comprenant : - la mise en contact de peptides du sérum issu de patients atteints de tuberculose active - la détection de la formation de complexes immuns à l'étape précédente, et - la sélection des peptides d'intérêt pour lesquels la valeur d'un ratio R est supérieure ou égale à 1,5, le ratio R étant la valeur de mesure de la formation de complexe immun sur la valeur de mesure obtenu à partir de l'échantillon contrôle.
FR1651610A 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation Active FR3048286B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1651610A FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation
CA3014034A CA3014034A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation
EP17712193.6A EP3420358A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation
CN201780013116.0A CN108885213A (zh) 2016-02-26 2017-02-24 免疫原性肽和其用途
PCT/FR2017/050418 WO2017144830A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation
US16/079,629 US20210199657A1 (en) 2016-02-26 2017-02-24 Immunogenic peptides and use thereof
JP2018544825A JP2019511708A (ja) 2016-02-26 2017-02-24 免疫原性ペプチド及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1651610A FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation

Publications (2)

Publication Number Publication Date
FR3048286A1 FR3048286A1 (fr) 2017-09-01
FR3048286B1 true FR3048286B1 (fr) 2021-01-22

Family

ID=56263826

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1651610A Active FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation

Country Status (7)

Country Link
US (1) US20210199657A1 (fr)
EP (1) EP3420358A1 (fr)
JP (1) JP2019511708A (fr)
CN (1) CN108885213A (fr)
CA (1) CA3014034A1 (fr)
FR (1) FR3048286B1 (fr)
WO (1) WO2017144830A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300688B6 (cs) * 1995-09-01 2009-07-15 Corixa Corporation Polypeptid, farmaceutický prostredek a vakcína s jeho obsahem, zpusob prípravy a použití polypeptidu, molekula rekombinantní DNA a její použití, expresní vektor, hostitelská bunka, fúsní porotein a diagnostický kit
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP2281198B1 (fr) * 2008-04-19 2013-01-02 New York University Peptide de mycobacterium tuberculosis immunodominants provenant de protéines de paroi cellulaire pour un diagnostic précoce et une immunisation
CN102124029A (zh) * 2008-05-26 2011-07-13 泰里安诊断有限公司 诊断由分枝杆菌引起的感染的方法和针对其的试剂
WO2013040142A2 (fr) * 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
CN102297968B (zh) * 2010-06-28 2013-10-30 程小星 辅助诊断结核病的试剂盒
WO2012164088A1 (fr) * 2011-06-03 2012-12-06 Universite Montpellier 2 Sciences Et Techniques Procédé de diagnostic de la tuberculose active
JP6317993B2 (ja) * 2014-05-07 2018-04-25 ポーラ化成工業株式会社 肌改善剤のスクリーニング方法
CN104020297B (zh) * 2014-06-10 2016-12-07 上海交通大学医学院 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途

Also Published As

Publication number Publication date
US20210199657A1 (en) 2021-07-01
CA3014034A1 (fr) 2017-08-31
CN108885213A (zh) 2018-11-23
JP2019511708A (ja) 2019-04-25
FR3048286A1 (fr) 2017-09-01
EP3420358A1 (fr) 2019-01-02
WO2017144830A1 (fr) 2017-08-31

Similar Documents

Publication Publication Date Title
Ducrotoy et al. A review of the basis of the immunological diagnosis of ruminant brucellosis
Delogu et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders
Richardus et al. Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh
Spensieri et al. Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans
JP2017184729A5 (fr)
WO2018229549A3 (fr) Système et procédé de reconstruction d'environnement numérique
CN106661764B (zh) 血凝抑制分析(hai)的自动化成像和分析
JP2012073273A5 (fr)
Pitarch et al. Seroprofiling at the Candida albicans protein species level unveils an accurate molecular discriminator for candidemia
EP3112800A3 (fr) Procede de mesure d'au moins une dimension d'un objet
Valentini et al. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis
FR3070498B1 (fr) Dispositif et procede de determination de la presence ou de l'absence et eventuellement du deplacement d'un objet contenu dans un logement
JP2018017729A (ja) 分析物を特徴付ける方法及びデバイス
SG10201908265UA (en) L-fabp immunoassay method and assay reagent used in said method
WO2021217140A3 (fr) Réactifs d'amélioration de la spécificité pour un test d'anticorps du covid-19
MX2019003288A (es) Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.
Agis et al. Use of anti-M. leprae phenolic glycolipid-I antibody detection for early diagnosis and prognosis of leprosy.
Ayubi et al. Do the tuberculin skin test and the QuantiFERON-TB Gold in-tube test agree in detecting latent tuberculosis among high-risk contacts? A systematic review and meta-analysis
US20130133423A1 (en) Device for detecting motions and method for detecting motions
FR3050535B1 (fr) Anticorps anti il17
CN102161695A (zh) 一种用于耐药结核血清学诊断的Rv1793重组蛋白
CN114297012B (zh) 一种检测设备精度的方法、装置、电子设备和存储介质
CN104766294A (zh) 自动化对位系统及方法
JP2011186543A (ja) データ処理方法およびデータ処理装置
TW201005847A (en) Inspecting method and inspecting equipment

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170901

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11